Psoriatic Arthritis Awareness

Healio spoke with two clinicians from Johns Hopkins University about the psoriatic arthritis treatment landscape, specifically touching on JAK inhibitor and interleukin-6 agents.

In this video series, Uzma Jalal Haque, MBBS, MD, associate professor of medicine, and Ana-Maria Orbai, MD, MPH, assistant professor of medicine and director of the Psoriatic Arthritis Program, discussed:

• recent FDA approvals, highlighting agents that have already show efficacy in other rheumatologic disease;
• “exciting” agents in the pipeline for the treatment of PsA;
• JAK inhibitors use in clinical practice, and the importance of discussing safety data with patients;
• what managing patients through a collaborative lens looks like in practice;
• why early screening is “critical”;
• the impact structural racism and personal bias have on the PsA care continuum; and
• awareness of PsA and what that means for clinicians compared with patients.

Disclosures:

Haques reports no relevant financial disclosures. Orbai reports received research funding to Johns Hopkins University from Abbvie, Amgen, Celgene, Janssen, Eli Lilly & Co. and Novartis; and consulting for Bristol Myers Squibb, Janssen, Eli Lilly & Co., Novartis, Pfizer, Sanofi and UCB.